Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
Total Valuation
Revelation Biosciences has a market cap or net worth of $2.79M. The enterprise value is -$3.94M.
Market Cap$2.79M
Enterprise Value-$3.94M
Share Statistics
Revelation Biosciences has 905,228 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding905,228
Owned by Insiders5.10%
Owned by Institutions0.51%
Financial Efficiency
Revelation Biosciences’s return on equity (ROE) is -3.19 and return on invested capital (ROIC) is -120.47%.
Return on Equity (ROE)-3.19
Return on Assets (ROA)-2.27
Return on Invested Capital (ROIC)-120.47%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee0.00
Profits Per Employee-1.88B
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Revelation Biosciences is >-0.01. Revelation Biosciences’s PEG ratio is >-0.01.
PE Ratio>-0.01
PS Ratio―
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, Revelation Biosciences had revenue of 0.00 and earned -15.04B in profits. Earnings per share was -8.77K.
Revenue0.00
Gross Profit0.00
Operating Income-7.98B
Pretax Income-15.04B
Net Income-15.04B
EBITDA-7.98B
Earnings Per Share (EPS)-8.77K
Cash Flow
In the last 12 months, operating cash flow was -18.32B and capital expenditures -38.34K, giving a free cash flow of -18.34B billion.
Operating Cash Flow-18.32B
Free Cash Flow-18.34B
Free Cash Flow per Share-20.26K
Dividends & Yields
Revelation Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change-90.43%
50-Day Moving Average3.37
200-Day Moving Average11.29
Relative Strength Index (RSI)49.67
Average Volume (3m)178.76K
Important Dates
Revelation Biosciences upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Revelation Biosciences as a current ratio of 3.43K, with Debt / Equity ratio of 0.00%
Current Ratio3.43K
Quick Ratio3.43K
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Revelation Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Revelation Biosciences EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of >-0.01.
EV to Sales0.00
EV to EBITDA>-0.01
EV to Free Cash Flow>-0.01
EV to Operating Cash Flow>-0.01
Balance Sheet
Revelation Biosciences has $6.50B in cash and marketable securities with $0.00 in debt, giving a net cash position of -$6.50B billion.
Cash & Marketable Securities$6.50B
Total Debt$0.00
Net Cash-$6.50B
Net Cash Per Share-$7.18K
Tangible Book Value Per Share$2.75K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Revelation Biosciences is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside549.35% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-115.81%